Annita Tanini Sells 1,224 Shares of Keros Therapeutics (NASDAQ:KROS) Stock

Key Points

• Insider sale: VP Annita Tanini sold 1,224 Keros Therapeutics shares for approximately $12,595 to cover tax withholding tied to vested equity awards, reducing her stake by 2.64%.
• Weak financial results: Keros reported a quarterly loss of $1.45 per share, missing the $1.34 consensus estimate, and analysts expect a full-year loss of $5.16 per share.
• Mixed market outlook: Shares recently traded at $10.95, well below the consensus analyst target of $20.50. Ratings remain mixed, with four Buy, three Hold, and two Sell recommendations, while institutional investors own 71.56% of the stock.

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) VP Annita Tanini sold 1,224 shares of Keros Therapeutics stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $12,594.96. Following the transaction, the vice president owned 45,144 shares of the company's stock, valued at $464,531.76. The trade was a 2.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Keros Therapeutics Trading Down 1.4%

Keros Therapeutics stock traded down $0.15 during mid-day trading on Thursday, hitting $10.95. The company had a trading volume of 203,071 shares, compared to its average volume of 339,802. Keros Therapeutics, Inc. has a 12 month low of $9.69 and a 12 month high of $22.55. The company has a market capitalization of $217.14 million, a PE ratio of -2.96 and a beta of 0.99. The stock's 50 day moving average price is $10.67 and its two-hundred day moving average price is $11.90.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Equities research analysts anticipate that Keros Therapeutics, Inc. will post -5.16 EPS for the current year.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Keros Therapeutics in the 2nd quarter worth $29,898,000. Vanguard Group Inc. raised its stake in Keros Therapeutics by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company's stock worth $43,011,000 after acquiring an additional 87,129 shares during the period. Nantahala Capital Management LLC bought a new position in shares of Keros Therapeutics in the second quarter worth approximately $15,091,483,000. Jacobs Levy Equity Management Inc. increased its stake in shares of Keros Therapeutics by 26.6% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 768,425 shares of the company's stock worth $15,645,000 after purchasing an additional 161,336 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Keros Therapeutics by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company's stock valued at $7,547,000 after purchasing an additional 205,022 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

KROS has been the topic of several analyst reports. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Zacks Research downgraded shares of Keros Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Wednesday, July 29th. Wall Street Zen downgraded Keros Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Sunday. Wells Fargo & Company reduced their target price on Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating for the company in a report on Tuesday, August 4th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $20.50.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source